This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
lung injury | 785 |
mg kg | 751 |
intensive care | 734 |
septic shock | 661 |
gene expression | 632 |
endothelial cells | 611 |
inflammatory response | 581 |
ng ml | 560 |
immune response | 503 |
present study | 492 |
control group | 463 |
acute lung | 432 |
nitric oxide | 414 |
mechanical ventilation | 374 |
pg ml | 373 |
critically ill | 360 |
care unit | 358 |
mrna expression | 357 |
epithelial cells | 351 |
inflammatory cytokines | 351 |
oxidative stress | 324 |
innate immune | 321 |
significantly higher | 318 |
blood pressure | 317 |
like receptor | 311 |
immune responses | 302 |
cell line | 302 |
significantly increased | 301 |
cell lines | 293 |
critical care | 290 |
immune system | 289 |
protein expression | 285 |
bone marrow | 284 |
ill patients | 284 |
acute respiratory | 281 |
flow cytometry | 280 |
important role | 280 |
significantly reduced | 279 |
peripheral blood | 277 |
blood flow | 276 |
severe sepsis | 275 |
organ failure | 273 |
two groups | 271 |
necrosis factor | 270 |
results suggest | 263 |
apache ii | 263 |
cell death | 259 |
western blot | 258 |
smooth muscle | 254 |
dendritic cells | 254 |
respiratory distress | 250 |
mean age | 244 |
cytokine production | 243 |
patients admitted | 235 |
significant differences | 226 |
statistically significant | 225 |
distress syndrome | 223 |
inflammatory responses | 223 |
dependent manner | 223 |
tumor necrosis | 222 |
cell surface | 221 |
cell proliferation | 221 |
nervous system | 219 |
growth factor | 216 |
mouse model | 215 |
significant difference | 213 |
data suggest | 213 |
cell types | 207 |
endothelial cell | 206 |
transcription factor | 206 |
lung tissue | 203 |
blood samples | 199 |
body weight | 195 |
significant increase | 195 |
mg ml | 193 |
performed using | 190 |
deficient mice | 188 |
statistical analysis | 187 |
septic patients | 187 |
cardiac output | 185 |
cd cd | 185 |
ml kg | 184 |
mrna levels | 182 |
spinal cord | 181 |
risk factors | 180 |
lps stimulation | 179 |
results indicate | 177 |
significantly lower | 177 |
ko mice | 176 |
lps group | 175 |
respiratory failure | 175 |
mortality rate | 174 |
wild type | 173 |
signaling pathways | 172 |
plasma levels | 172 |
animal models | 171 |
multiple organ | 171 |
immune cells | 169 |
cell activation | 169 |
signal transduction | 169 |
transgenic mice | 168 |
taken together | 166 |
protein kinase | 165 |
icu patients | 165 |
central nervous | 161 |
expression levels | 161 |
proinflammatory cytokines | 160 |
organ dysfunction | 160 |
icu admission | 155 |
previous studies | 154 |
reactive oxygen | 154 |
adhesion molecules | 154 |
lps challenge | 154 |
time points | 154 |
severe hepatitis | 153 |
results show | 153 |
time pcr | 153 |
binding protein | 153 |
may contribute | 153 |
heart failure | 153 |
arterial pressure | 151 |
inflammatory cytokine | 151 |
renal failure | 150 |
arterial blood | 150 |
hospital mortality | 148 |
inflammatory mediators | 148 |
amino acid | 148 |
western blotting | 148 |
innate immunity | 147 |
lps injection | 146 |
high levels | 145 |
cardiac surgery | 143 |
lung inflammation | 143 |
induced lung | 143 |
surfactant protein | 141 |
heart rate | 141 |
cardiac arrest | 140 |
blot analysis | 140 |
positive cells | 140 |
icu stay | 140 |
type i | 140 |
wt mice | 140 |
stem cells | 139 |
mononuclear cells | 139 |
significantly decreased | 138 |
tumor cells | 138 |
gestational age | 137 |
like receptors | 135 |
protein levels | 134 |
brain injury | 133 |
molecular mechanisms | 133 |
class i | 133 |
ml min | 132 |
data indicate | 131 |
mast cells | 131 |
pulmonary artery | 131 |
logistic regression | 130 |
oxygen species | 130 |
escherichia coli | 130 |
ex vivo | 130 |
side effects | 130 |
activated protein | 129 |
signaling pathway | 129 |
muscle cells | 127 |
serum levels | 127 |
determine whether | 127 |
acute phase | 126 |
findings suggest | 126 |
vascular permeability | 125 |
care units | 124 |
transcription factors | 124 |
measured using | 124 |
previously described | 124 |
cell responses | 123 |
ii score | 122 |
lps administration | 122 |
cell cycle | 121 |
results showed | 120 |
alveolar macrophages | 119 |
tlr signaling | 118 |
first time | 118 |
mechanically ventilated | 118 |
microglial cells | 118 |
clinical trials | 118 |
control mice | 117 |
lung tissues | 116 |
patients undergoing | 115 |
negative bacteria | 115 |
inhibitory effect | 115 |
dna damage | 115 |
may play | 114 |
university hospital | 114 |
pulmonary vascular | 113 |
whole blood | 113 |
room temperature | 113 |
induced acute | 113 |
pregnant women | 112 |
mhc class | 112 |
vascular endothelial | 111 |
glial cells | 111 |
survival rate | 109 |
tissue damage | 109 |
type mice | 108 |
cell culture | 108 |
may also | 106 |
increased expression | 106 |
oxide synthase | 106 |
knockout mice | 105 |
inflammatory cells | 105 |
cord uid | 105 |
systemic inflammatory | 105 |
multiple sclerosis | 105 |
doc id | 105 |
observational study | 104 |
adhesion molecule | 104 |
liver disease | 104 |
significantly different | 104 |
critical role | 103 |
mean arterial | 103 |
protective effect | 103 |
nkt cells | 102 |
animal model | 101 |
cd cells | 101 |
inflammatory diseases | 101 |
liver failure | 101 |
induced ali | 100 |
extracellular matrix | 99 |
trauma patients | 99 |
adaptive immune | 99 |
patients received | 98 |
plasma membrane | 98 |
time point | 98 |
determined using | 98 |
tlr expression | 98 |
differentially expressed | 97 |
host defense | 97 |
bronchoalveolar lavage | 97 |
patients without | 97 |
medical center | 96 |
results demonstrate | 96 |
culture medium | 96 |
significant reduction | 96 |
heme oxygenase | 96 |
influenza virus | 95 |
tidal volume | 95 |
poly i | 95 |
total rna | 95 |
healthy volunteers | 95 |
hepatic encephalopathy | 94 |
pulmonary disease | 94 |
previously reported | 94 |
central venous | 94 |
monoclonal antibodies | 93 |
amino acids | 93 |
chronic obstructive | 92 |
blood vessels | 92 |
stem cell | 92 |
rheumatoid arthritis | 92 |
data show | 91 |
study period | 91 |
bl mice | 91 |
cell type | 91 |
risk factor | 91 |
rat model | 91 |
cohort study | 91 |
fold increase | 91 |
monoclonal antibody | 90 |
lymph nodes | 90 |
group i | 90 |
pulmonary edema | 89 |
day mortality | 89 |
real time | 89 |
also found | 89 |
type ii | 89 |
prospective study | 89 |
may lead | 88 |
vascular resistance | 88 |
mass spectrometry | 88 |
trained immunity | 88 |
molecular weight | 87 |
key role | 87 |
significant decrease | 87 |
type diabetes | 87 |
mg dl | 86 |
systemic inflammation | 86 |
ang ii | 86 |
long term | 86 |
treated mice | 86 |
recent studies | 85 |
cell adhesion | 85 |
myocardial infarction | 85 |
nuclear factor | 84 |
pulmonary surfactant | 84 |
regression analysis | 84 |
statistical significance | 83 |
blood gas | 83 |
analysis revealed | 83 |
within hours | 83 |
obstructive pulmonary | 82 |
adult patients | 82 |
inflammatory effects | 82 |
increased levels | 82 |
th cells | 82 |
cancer cells | 82 |
increased risk | 82 |
ventilated patients | 81 |
blood cells | 81 |
treated animals | 81 |
adaptive immunity | 81 |
signalling pathway | 81 |
cell migration | 81 |
oxygen saturation | 81 |
replacement therapy | 80 |
activating factor | 80 |
previously shown | 80 |
wistar rats | 80 |
receptor antagonist | 80 |
first trimester | 80 |
white matter | 80 |
class ii | 80 |
venous blood | 80 |
blood mononuclear | 79 |
cardiac index | 79 |
three groups | 79 |
tissue injury | 79 |
endothelial barrier | 79 |
influenza infection | 79 |
sofa score | 79 |
cytokine levels | 78 |
peritoneal macrophages | 78 |
gas exchange | 78 |
higher levels | 78 |
cell viability | 78 |
fatty acid | 78 |
apoptotic cells | 78 |
brain barrier | 78 |
kg min | 78 |
years old | 78 |
emergency department | 78 |
high risk | 78 |
also observed | 77 |
pulmonary hypertension | 77 |
nk cells | 77 |
specific cd | 77 |
breast cancer | 77 |
patients treated | 76 |
nlrp inflammasome | 76 |
retrospective study | 76 |
renal function | 76 |
barrier function | 76 |
way anova | 76 |
protective effects | 76 |
control animals | 75 |
protein level | 75 |
epithelial cell | 75 |
reperfusion injury | 75 |
hospital stay | 75 |
bacterial infection | 75 |
bacterial infections | 75 |
pulmonary fibrosis | 75 |
reactive protein | 74 |
significant changes | 74 |
infectious diseases | 74 |
analyzed using | 74 |
oxygen delivery | 74 |
cell cultures | 74 |
blood glucose | 74 |
lps treatment | 74 |
viral infection | 74 |
mortality rates | 74 |
growth factors | 74 |
united kingdom | 73 |
respiratory tract | 73 |
critical illness | 72 |
two different | 72 |
clinical trial | 72 |
fetal growth | 72 |
previous study | 72 |
consecutive patients | 72 |
left ventricular | 72 |
data demonstrate | 72 |
liver transplantation | 72 |
virus infection | 71 |
blood gases | 71 |
lung disease | 71 |
mm hg | 71 |
chronic inflammatory | 71 |
analysis showed | 70 |
adverse effects | 70 |
days post | 70 |
hemorrhagic shock | 70 |
least one | 70 |
one patient | 70 |
mast cell | 70 |
cytokine release | 69 |
crucial role | 69 |
ali ards | 69 |
hek cells | 69 |
schwann cells | 69 |
pao fio | 69 |
red blood | 68 |
mice showed | 68 |
pivotal role | 68 |
progenitor cells | 68 |
fatty acids | 68 |
assessed using | 68 |
cell membrane | 67 |
healthy controls | 67 |
microglial activation | 67 |
blood loss | 67 |
time course | 67 |
lavage fluid | 67 |
mouse models | 67 |
renal replacement | 67 |
first hours | 67 |
patients died | 67 |
sirna nanoparticles | 66 |
vitro studies | 66 |
icu mortality | 66 |
hydrogen peroxide | 66 |
potential therapeutic | 66 |
kidney injury | 66 |
may provide | 66 |
specific antibodies | 66 |
mechanisms underlying | 65 |
investigate whether | 65 |
acute renal | 65 |
cells expressing | 65 |
vascular smooth | 65 |
widely used | 65 |
saps ii | 65 |
single cell | 65 |
study design | 64 |
inflammatory processes | 64 |
pulmonary inflammation | 64 |
surface expression | 64 |
antigen presentation | 64 |
beneficial effects | 64 |
ob gyn | 64 |
binding site | 64 |
airway pressure | 64 |
skeletal muscle | 64 |
angiotensin ii | 63 |
high mortality | 63 |
dorsal funiculus | 63 |
may represent | 63 |
nod mice | 63 |
major role | 63 |
central role | 63 |
one hour | 62 |
electron microscopy | 62 |
cardiac function | 62 |
sqad vite | 62 |
small intestine | 62 |
current study | 62 |
proinflammatory cytokine | 62 |
microvascular endothelial | 62 |
significantly associated | 62 |
ischemia reperfusion | 62 |
respiratory syndrome | 62 |
tumor cell | 62 |
murine model | 62 |
respiratory rate | 62 |
ttp ko | 61 |
commercially available | 61 |
ms ms | 61 |
coupled receptors | 61 |
coronary artery | 61 |
bovine serum | 61 |
pressure support | 61 |
mesothelial cells | 61 |
high affinity | 61 |
treated cells | 61 |
well plates | 61 |
neutrophil recruitment | 61 |
informed consent | 61 |
tnf production | 61 |
adverse events | 61 |
high dose | 61 |
poorly understood | 60 |
inducible nitric | 60 |
three times | 60 |
pseudomonas aeruginosa | 60 |
predictive value | 60 |
copd patients | 60 |
anp high | 60 |
lung cancer | 60 |
lps induced | 60 |
myeloid cells | 60 |
presenting cells | 60 |
mice compared | 59 |
mice treated | 59 |
protein synthesis | 59 |
investigated whether | 59 |
challenged ttp | 59 |
preliminary results | 59 |
amniotic fluid | 59 |
autoimmune diseases | 59 |
inflammatory bowel | 59 |
considered significant | 58 |
median age | 58 |
acute kidney | 58 |
cells showed | 58 |
united states | 58 |
study showed | 58 |
plasma concentrations | 58 |
significantly elevated | 58 |
increased significantly | 58 |
signalling pathways | 57 |
ics ii | 57 |
birth weight | 57 |
inhibitory effects | 57 |
nuclear translocation | 57 |
following lps | 57 |
control groups | 57 |
human monocytes | 57 |
primary human | 57 |
group ii | 57 |
low dose | 57 |
intestinal epithelial | 57 |
recent years | 57 |
immune cell | 57 |
severe acute | 57 |
viral infections | 57 |
expression level | 57 |
cell response | 57 |
commonly used | 56 |
significantly inhibited | 56 |
chronic liver | 56 |
well known | 56 |
three different | 56 |
receptor expression | 56 |
low levels | 56 |
clinical studies | 56 |
cell receptor | 56 |
study group | 56 |
mice lacking | 56 |
tlr ligands | 56 |
family members | 56 |
highly expressed | 56 |
inkt cells | 56 |
inflammatory effect | 56 |
receptor activation | 56 |
membrane potential | 56 |
gram negative | 56 |
ca i | 56 |
two patients | 55 |
ginsenoside rb | 55 |
inflammatory conditions | 55 |
mechanisms involved | 55 |
treated rats | 55 |
significant correlation | 55 |
staphylococcus aureus | 55 |
showed significant | 55 |
tissue factor | 55 |
liver injury | 55 |
recognition receptors | 55 |
total number | 55 |
year period | 54 |
clinical signs | 54 |
total protein | 54 |
mean values | 54 |
outer membrane | 54 |
fold higher | 54 |
liver cirrhosis | 54 |
antigen presenting | 54 |
brain tissue | 54 |
tyrosine kinase | 54 |
adipose tissue | 54 |
positive control | 54 |
mesenchymal stem | 53 |
cytokine secretion | 53 |
prospective observational | 53 |
acute pancreatitis | 53 |
lactate levels | 53 |
therapeutic potential | 53 |
neurodegenerative diseases | 53 |
healthy subjects | 53 |
blood cell | 53 |
dose dependent | 53 |
endothelial growth | 53 |
ovarian cancer | 53 |
cell growth | 53 |
high concentrations | 53 |
trophoblast cells | 53 |
preterm birth | 53 |
confocal microscopy | 53 |
may result | 53 |
viral replication | 52 |
gel electrophoresis | 52 |
also significantly | 52 |
infl ammatory | 52 |
promoter activity | 52 |
acute inflammation | 52 |
cell population | 52 |
per group | 52 |
month period | 52 |
new therapeutic | 52 |
recombinant human | 52 |
cell differentiation | 52 |
several studies | 52 |
university medical | 52 |
quantitative real | 52 |
santa cruz | 51 |
human lung | 51 |
serum albumin | 51 |
cancer cell | 51 |
liver function | 51 |
bowel disease | 51 |
induced activation | 51 |
tg mice | 51 |
cd expression | 51 |
natural killer | 51 |
also known | 51 |
expression pattern | 51 |
endothelial permeability | 51 |
early stage | 51 |
gastrointestinal tract | 51 |
inclusion criteria | 51 |
cell signaling | 50 |
regulatory factor | 50 |
cell wall | 50 |
antibiotic therapy | 50 |
increased mortality | 50 |
surgical patients | 50 |
vg vd | 50 |
preterm delivery | 50 |
significantly greater | 50 |
traumatic brain | 50 |
mpo activity | 50 |
transforming growth | 50 |
binding sites | 50 |
high pmn | 50 |
remains unclear | 49 |
necrotizing enterocolitis | 49 |
head injury | 49 |
elderly patients | 49 |
mrna level | 49 |
cecal ligation | 49 |
short term | 49 |
differential expression | 49 |
lipid peroxidation | 49 |
future studies | 49 |
induced inflammation | 49 |
different time | 49 |
dendritic cell | 49 |
pharmakologie und | 49 |
negative control | 49 |
tumour necrosis | 49 |
demographic data | 49 |
menstrual cycle | 49 |
health care | 49 |
data obtained | 49 |
even though | 49 |
vite nps | 49 |
animal studies | 49 |
hospital discharge | 49 |
response syndrome | 49 |
linked immunosorbent | 49 |
cardiogenic shock | 49 |
genes involved | 49 |
target genes | 49 |
neutrophil infiltration | 49 |
glucose levels | 49 |
treatment group | 48 |
oxygen consumption | 48 |
tumor growth | 48 |
coupled receptor | 48 |
kg body | 48 |
disease severity | 48 |
diabetes mellitus | 48 |
group compared | 48 |
complement activation | 48 |
lung function | 48 |
standard deviation | 48 |
inflammatory cell | 48 |
studies showed | 48 |
acute inflammatory | 48 |
postoperative period | 48 |
analysis using | 48 |
surfactant proteins | 48 |
endoplasmic reticulum | 48 |
vitro model | 48 |
protective role | 48 |
biological activity | 48 |
animal experiments | 48 |
metabolic acidosis | 48 |
multivariate analysis | 48 |
may help | 47 |
infected cells | 47 |
und toxikologie | 47 |
cell count | 47 |
preterm labor | 47 |
infected mice | 47 |
inflammatory properties | 47 |
wide range | 47 |
dawley rats | 47 |
induced apoptosis | 47 |
growth restriction | 47 |
included patients | 47 |
compared using | 47 |
pilot study | 47 |
patients suffering | 47 |
among patients | 47 |
host response | 47 |
kg day | 47 |
higher mortality | 46 |
blood cultures | 46 |
wound healing | 46 |
san diego | 46 |
three days | 46 |
chronic inflammation | 46 |
first days | 46 |
novel therapeutic | 46 |
human myometrium | 46 |
stimulating factor | 46 |
acute liver | 46 |
uric acid | 46 |
immunosorbent assay | 46 |
bacterial translocation | 46 |
inflammatory stimuli | 46 |
free radicals | 46 |
clinical manifestations | 46 |
pattern recognition | 46 |
weight loss | 46 |
elevated levels | 46 |
patients receiving | 46 |
medical university | 45 |
therapeutic strategy | 45 |
therapeutic strategies | 45 |
free radical | 45 |
cytokine expression | 45 |
blood transfusion | 45 |
clinically relevant | 45 |
chemokine receptor | 45 |
induced inflammatory | 45 |
different types | 45 |
airway inflammation | 45 |
risk assessment | 45 |
fat diet | 45 |
kupffer cells | 45 |
different cell | 45 |
macrophage activation | 45 |
receptor signaling | 45 |
cell survival | 45 |
ethics committee | 45 |
inflammatory reaction | 45 |
may explain | 45 |
age years | 45 |
expressed genes | 45 |
associated molecular | 44 |
monocytes macrophages | 44 |
host cells | 44 |
macrophage cell | 44 |
potential role | 44 |
kg bw | 44 |
significantly improved | 44 |
chain reaction | 44 |
carbon monoxide | 44 |
reactive astrocytes | 44 |
tlr activation | 44 |
pathological changes | 44 |
th day | 44 |
provide evidence | 44 |
umbilical cord | 44 |
heat shock | 44 |
pulmonary embolism | 44 |
cell function | 44 |
umbilical vein | 44 |
i molecules | 44 |
positive correlation | 44 |
therapeutic target | 44 |
similar results | 44 |
nadph oxidase | 44 |
described previously | 44 |
ms patients | 44 |
systemic vascular | 44 |
defi cient | 44 |
heart disease | 44 |
neuropathic pain | 43 |
cardiac hypertrophy | 43 |
mobility group | 43 |
converting enzyme | 43 |
blood volume | 43 |
intraperitoneal injection | 43 |
studies will | 43 |
study demonstrates | 43 |
inflammatory markers | 43 |
urinary tract | 43 |
pregnant rats | 43 |
ros production | 43 |
cells express | 43 |
ards patients | 43 |
flow cytometric | 43 |
cells treated | 43 |
dry weight | 43 |
better understanding | 43 |
vascular tone | 43 |
ng cells | 43 |
therapeutic hypothermia | 43 |
immune activation | 43 |
clinical course | 43 |
body temperature | 43 |
hepatorenal syndrome | 43 |
endotoxic shock | 43 |
intravenous injection | 43 |
beneficial effect | 43 |
closely related | 42 |
weeks gestation | 42 |
derived macrophages | 42 |
intercellular adhesion | 42 |
right ventricular | 42 |
pelvic pain | 42 |
also increased | 42 |
mixed venous | 42 |
clinical practice | 42 |
cell subsets | 42 |
levels increased | 42 |
dna repair | 42 |
cell populations | 42 |
fetal membranes | 42 |
first day | 42 |
ejection fraction | 42 |
organ injury | 42 |
platelet count | 42 |
platelet aggregation | 42 |
ml lps | 42 |
white blood | 42 |
cardiovascular disease | 42 |
portal vein | 42 |
alveolar epithelial | 42 |
map kinase | 42 |
days later | 42 |
blood coagulation | 41 |
therapeutic effect | 41 |
group box | 41 |
large number | 41 |
toxic effects | 41 |
within days | 41 |
cigarette smoke | 41 |
poor outcome | 41 |
activated microglia | 41 |
care medicine | 41 |
weight gain | 41 |
clinical data | 41 |
ad libitum | 41 |
spontaneous breathing | 41 |
fetal brain | 41 |
ug ml | 41 |
human umbilical | 41 |
inflammatory process | 41 |
igg liposomes | 41 |
well tolerated | 41 |
surface area | 41 |
human endothelial | 41 |
quantitative rt | 41 |
sirna nanoparticle | 41 |
male wistar | 41 |
leukocyte recruitment | 41 |
icu discharge | 41 |
urine output | 41 |
factor alpha | 41 |
cancer patients | 41 |
protein concentration | 41 |
immunohistochemical analysis | 41 |
sepsis syndrome | 41 |
injured lungs | 41 |
transcriptional regulation | 40 |
buffered saline | 40 |
induced il | 40 |
bacterial lipopolysaccharide | 40 |
effector cells | 40 |
transgenic mouse | 40 |
th cytokines | 40 |
cell counts | 40 |
analysed using | 40 |
respiratory system | 40 |
preliminary data | 40 |
hemodynamic parameters | 40 |
cesarean section | 40 |
decreased significantly | 40 |
systemic circulation | 40 |
disease progression | 40 |
results obtained | 40 |
pulmonary microvascular | 40 |
pulmonary function | 40 |
cell apoptosis | 40 |
scoring system | 40 |
stromal cells | 40 |
facs analysis | 40 |
studies suggest | 40 |
early phase | 40 |
lps exposure | 40 |
study shows | 40 |
tissue samples | 40 |
expression profiles | 40 |
exact test | 40 |
strand breaks | 40 |
findings indicate | 40 |
cell infiltration | 40 |
cytokine il | 40 |
ion channels | 40 |
disseminated intravascular | 40 |
plasma cells | 39 |
lung epithelial | 39 |
cells using | 39 |
mycobacterium tuberculosis | 39 |
studies using | 39 |
cell development | 39 |
abdominal surgery | 39 |
inos expression | 39 |
time rt | 39 |
molecular patterns | 39 |
target cells | 39 |
bile acid | 39 |
cells may | 39 |
venous pressure | 39 |
surgical icu | 39 |
cystic fibrosis | 39 |
binding proteins | 39 |
plasminogen activator | 39 |
portal hypertension | 39 |
essential role | 39 |
authors declare | 39 |
therapeutic intervention | 39 |
study aimed | 39 |
peritoneal cavity | 39 |
primary outcome | 39 |
platelet activation | 39 |
physiological conditions | 39 |
polymerase chain | 39 |
culture media | 39 |
invasive ventilation | 39 |
control cells | 38 |
brain regions | 38 |
culture system | 38 |
cerebral cortex | 38 |
host immune | 38 |
retrospective cohort | 38 |
pleural effusion | 38 |
pl flux | 38 |
experimental model | 38 |
human peripheral | 38 |
lung diseases | 38 |
high fat | 38 |
usp expression | 38 |
evidence suggests | 38 |
underlying mechanisms | 38 |
crp levels | 38 |
induced expression | 38 |
fluorescence microscopy | 38 |
drinking water | 38 |
exclusion criteria | 38 |
infl ammation | 38 |
quantitative pcr | 38 |
clinical outcomes | 38 |
fl uid | 38 |
bd biosciences | 38 |
immune complexes | 38 |
surface markers | 38 |
cord blood | 38 |
pulmonary arterial | 38 |
streptococcus pneumoniae | 38 |
morphological changes | 38 |
clinical outcome | 38 |
data analysis | 38 |
reporter gene | 38 |
normal human | 37 |
ultrasound stimulation | 37 |
previous reports | 37 |
last years | 37 |
vitro experiments | 37 |
two weeks | 37 |
cell number | 37 |
cytokine response | 37 |
fluid resuscitation | 37 |
linear regression | 37 |
independent experiments | 37 |
candida albicans | 37 |
gene transcription | 37 |
significant change | 37 |
significantly less | 37 |
enzyme activity | 37 |
retrospective analysis | 37 |
also showed | 37 |
female mice | 37 |
induced cytokine | 37 |
blood culture | 37 |
therapeutic targets | 37 |
vivo studies | 37 |
systemic lupus | 37 |
five patients | 37 |
secondary antibody | 37 |
thermo fisher | 37 |
roc curve | 37 |
tlr agonists | 37 |
early diagnosis | 37 |
endothelial dysfunction | 37 |
intravascular coagulation | 37 |
transduction pathways | 37 |
renal dysfunction | 36 |
interferon regulatory | 36 |
cytokine profile | 36 |
shock patients | 36 |
high doses | 36 |
protease inhibitor | 36 |
six patients | 36 |
severe ards | 36 |
takes place | 36 |
oxidative damage | 36 |
women undergoing | 36 |
important roles | 36 |
mice received | 36 |
human skin | 36 |
studied patients | 36 |
cervical ripening | 36 |
pcr analysis | 36 |
differentially regulated | 36 |
cell lysates | 36 |
primary antibodies | 36 |
healthy donors | 36 |
inflamed lungs | 36 |
randomized controlled | 36 |
antibody response | 36 |
mitochondrial membrane | 36 |
serum creatinine | 36 |
one day | 36 |
previously demonstrated | 36 |
molecular mechanism | 36 |
evaluated using | 36 |
cytokine storm | 36 |
cient mice | 36 |
functional role | 36 |
may cause | 36 |
major cause | 36 |
negative regulator | 36 |
controlled trial | 35 |
chemokine receptors | 35 |
patients underwent | 35 |
markedly reduced | 35 |
odds ratio | 35 |
previous work | 35 |
insulin resistance | 35 |
producing cells | 35 |
patients showed | 35 |
body mass | 35 |
cells per | 35 |
major surgery | 35 |
small molecule | 35 |
significantly enhanced | 35 |
possible role | 35 |
normal range | 35 |
lymphoid tissue | 35 |
severe head | 35 |
induced cell | 35 |
three patients | 35 |
human neutrophils | 35 |
group received | 35 |
one year | 35 |
dependent signaling | 35 |
intracellular ca | 35 |
induced ards | 35 |
per day | 35 |
intestinal mucosa | 35 |
induced tnf | 35 |
actin cytoskeleton | 35 |
living cells | 35 |
high level | 35 |
patients required | 35 |
lupus erythematosus | 35 |
tract infection | 35 |
protein kinases | 35 |
mice exhibited | 35 |
cx cr | 35 |
laboratory animals | 35 |
tissue oxygenation | 34 |
artery catheter | 34 |
acute myocardial | 34 |
significant increases | 34 |
two hours | 34 |
cerebral artery | 34 |
may affect | 34 |
square test | 34 |
significantly attenuated | 34 |
neutrophil migration | 34 |
signaling molecules | 34 |
hours later | 34 |
injury induced | 34 |
fusion protein | 34 |
care patients | 34 |
precursor cells | 34 |
year old | 34 |
transient receptor | 34 |
treatment groups | 34 |
receptor potential | 34 |
treated group | 34 |
inflammatory activity | 34 |
glasgow coma | 34 |
plasma samples | 34 |
leukocyte adhesion | 34 |
studies show | 34 |
teaching hospital | 34 |
mechanical stretch | 34 |
lymph node | 34 |
microglia activation | 34 |
clinical symptoms | 34 |
mediated signaling | 34 |
leading cause | 34 |
microarray analysis | 34 |
oral administration | 34 |
tlr ligand | 34 |
severe trauma | 34 |
low concentrations | 34 |
superoxide dismutase | 34 |
tissue sections | 34 |
expression analysis | 34 |
identified using | 34 |
heart surgery | 34 |
using elisa | 34 |
hela cells | 34 |
human macrophages | 34 |
intravital microscopy | 34 |
xanthine oxidase | 34 |
cells stimulated | 34 |
well established | 34 |
animals treated | 33 |
protein coupled | 33 |
stress response | 33 |
tight junction | 33 |
membrane protein | 33 |
mouse lung | 33 |
positive bacteria | 33 |
syncytial virus | 33 |
normal saline | 33 |
kinase inhibitor | 33 |
neural stem | 33 |
dysfunction syndrome | 33 |
cytokines il | 33 |
luciferase reporter | 33 |
experimental models | 33 |
mass index | 33 |
data suggests | 33 |
lower levels | 33 |
acquired pneumonia | 33 |
different concentrations | 33 |
serum il | 33 |
bal fluid | 33 |
mg protein | 33 |
promoter region | 33 |
serum samples | 33 |
survival time | 33 |
data showed | 33 |
first step | 33 |
lung sections | 33 |
pl synthesis | 33 |
plasma concentration | 33 |
remained unchanged | 33 |
respiratory syncytial | 33 |
type iii | 32 |
results indicated | 32 |
hla class | 32 |
multiple trauma | 32 |
marked increase | 32 |
complement system | 32 |
organ damage | 32 |
pathway analysis | 32 |
study suggests | 32 |
coagulation factors | 32 |
estrogen receptor | 32 |
blood lactate | 32 |
one week | 32 |
reverse transcription | 32 |
connective tissue | 32 |
gene silencing | 32 |
neuronal activity | 32 |
cell functions | 32 |
carotid artery | 32 |
artery bypass | 32 |
inflammatory disease | 32 |
jugular vein | 32 |
frequently used | 32 |
rat brain | 32 |
freshly isolated | 32 |
polymicrobial sepsis | 32 |
mouse line | 32 |
low molecular | 32 |
data collection | 32 |
inflammatory disorders | 32 |
blood vessel | 32 |
activated macrophages | 32 |
university school | 32 |
lung surfactant | 32 |
expression patterns | 32 |
poor prognosis | 32 |
therapeutic agents | 32 |
quantified using | 32 |
induced sepsis | 32 |
fisher scientific | 32 |
clinical study | 32 |
inflammatory factors | 32 |
also shown | 32 |
stimulated pbmc | 32 |
healthy individuals | 32 |
natriuretic peptide | 32 |
culture supernatants | 32 |
drug delivery | 32 |
animal care | 32 |
patients developed | 32 |
blood levels | 32 |
lps induces | 32 |
also demonstrated | 31 |
cell numbers | 31 |
mouse lungs | 31 |
average age | 31 |
different levels | 31 |
early pregnancy | 31 |
marrow cells | 31 |
signaling cascade | 31 |
liver diseases | 31 |
atrial fibrillation | 31 |
following treatment | 31 |
cell suspensions | 31 |
negative predictive | 31 |
infected patients | 31 |
severity score | 31 |
pathological conditions | 31 |
endothelial activation | 31 |
arachidonic acid | 31 |
histological analysis | 31 |
splenic ultrasound | 31 |
endotracheal tube | 31 |
underlying mechanism | 31 |
adult mice | 31 |
thermal injury | 31 |
oral insulin | 31 |
first line | 31 |
stroke volume | 31 |
melanoma cells | 31 |
mean sd | 31 |
lg ml | 31 |
male mice | 31 |
pulmonary endothelial | 31 |
transcript levels | 31 |
medical school | 31 |
stranded rna | 31 |
largely unknown | 31 |
weeks old | 31 |
glycyrrhizic acid | 31 |
herpes simplex | 31 |
hospital cardiac | 31 |
expression profile | 31 |
folic acid | 31 |
tlr agonist | 31 |
mammalian cells | 31 |
trend towards | 31 |
lps alone | 31 |
lpeg sirna | 31 |
control study | 31 |
second messenger | 31 |
icu length | 30 |
may influence | 30 |
phagocytic cells | 30 |
adrenergic receptor | 30 |
injury severity | 30 |
two days | 30 |
therapeutic approaches | 30 |
inflammasome activation | 30 |
intracellular calcium | 30 |
cardiopulmonary bypass | 30 |
treated patients | 30 |
mutant mice | 30 |
ng glia | 30 |
human endometrial | 30 |
patients may | 30 |
dependent activation | 30 |
guinea pig | 30 |
partial pressure | 30 |
mean value | 30 |
capillary permeability | 30 |
energy metabolism | 30 |
expression profiling | 30 |
vitro assays | 30 |
lysis buffer | 30 |
cytotoxic effects | 30 |
assay kit | 30 |
opc differentiation | 30 |
dorsal root | 30 |
three independent | 30 |
cellular immune | 30 |
total cell | 30 |
conditioned medium | 30 |
wildtype mice | 30 |
including il | 30 |
associated pneumonia | 30 |
related genes | 30 |
rabbit polyclonal | 30 |
blood monocytes | 30 |
induced increase | 30 |
patients requiring | 30 |
systolic blood | 30 |
within minutes | 30 |
cellular uptake | 30 |
highly conserved | 30 |
general hospital | 30 |
middle cerebral | 30 |
negative controls | 30 |
ct scan | 30 |
highly significant | 30 |
probably due | 30 |
antibiotic treatment | 30 |
cell membranes | 30 |
times higher | 30 |
mapk signaling | 30 |
cells via | 30 |
bacterial endotoxin | 30 |
injected intraperitoneally | 30 |
better understand | 30 |
different stages | 30 |
proinflammatory mediators | 30 |
tissue repair | 30 |
cultured human | 30 |
studies demonstrated | 30 |
mammary gland | 30 |
group showed | 30 |
apoptotic cell | 30 |
receiver operating | 29 |
eoc cells | 29 |
human placenta | 29 |
activated neutrophils | 29 |
decision making | 29 |
polyclonal antibody | 29 |
mediated immune | 29 |
using specific | 29 |
total body | 29 |
inflammatory reactions | 29 |
murine macrophages | 29 |
systematic review | 29 |
per well | 29 |
coma scale | 29 |
tested whether | 29 |
tnf receptor | 29 |
model system | 29 |
conditioned media | 29 |
results provide | 29 |
cells within | 29 |
nkt cell | 29 |
cells transfected | 29 |
vein endothelial | 29 |
sample size | 29 |
rna interference | 29 |
using flow | 29 |
factor receptor | 29 |
almost completely | 29 |
artery pressure | 29 |
may serve | 29 |
challenged mice | 29 |
prothrombin time | 29 |
higher incidence | 29 |
also involved | 29 |
induced arthritis | 29 |
sepsis patients | 29 |
gold standard | 29 |
important factor | 29 |
tight junctions | 29 |
intestinal mucosal | 29 |
femoral head | 29 |
higher concentrations | 29 |
post hoc | 29 |
weight ratio | 29 |
expressing cells | 29 |
acute physiology | 29 |
randomly assigned | 29 |
factors associated | 29 |
butanol extract | 29 |
regulated genes | 29 |
mediated activation | 29 |
low doses | 29 |
clinical use | 29 |
prospectively studied | 29 |
endothelial glycocalyx | 29 |
antibody responses | 29 |
hours post | 29 |
deficient cells | 29 |
bile acids | 29 |
dna adducts | 29 |
flow rate | 29 |
liquid chromatography | 29 |
glial cell | 29 |
considered statistically | 29 |
studies indicate | 29 |
negative correlation | 29 |
fungal infections | 29 |
recently shown | 29 |
significant improvement | 29 |
reduced expression | 29 |
dna methylation | 29 |
abdominal sepsis | 29 |
vascular endothelium | 29 |
gastrointestinal bleeding | 29 |
medical records | 29 |
gas analysis | 29 |
continuous infusion | 29 |
serum lactate | 28 |
data provide | 28 |
seven days | 28 |
host cell | 28 |
new insights | 28 |
activated receptor | 28 |
ulcerative colitis | 28 |
dependent pathway | 28 |
guinea pigs | 28 |
fetal plasma | 28 |
present work | 28 |
human cd | 28 |
differ significantly | 28 |
also reduced | 28 |
cells play | 28 |
phagocytic activity | 28 |
deleterious effects | 28 |
recent data | 28 |
matched controls | 28 |
study demonstrated | 28 |
adult respiratory | 28 |
corticosteroid treatment | 28 |
increased susceptibility | 28 |
inflammatory signaling | 28 |
gene promoter | 28 |
constitutively expressed | 28 |
decidual cells | 28 |
cardiac fibroblasts | 28 |
inflammatory protein | 28 |
glioma cells | 28 |
negative bacterial | 28 |
human keratinocytes | 28 |
secretory phase | 28 |
data set | 28 |
granulosa cells | 28 |
significantly correlated | 28 |
expression data | 28 |
recent study | 28 |
ttp myeko | 28 |
target gene | 28 |
cytokines tnf | 28 |
antigen processing | 28 |
plasma volume | 28 |
like cells | 28 |
ml vs | 28 |
immune function | 28 |
lamina propria | 28 |
listeria monocytogenes | 28 |
public health | 28 |
whitney test | 28 |
normal pregnancy | 28 |
follicular fluid | 28 |
fetal bovine | 28 |
optic nerve | 28 |
study provides | 28 |
serine protease | 28 |
day post | 28 |
wide variety | 28 |
binding activity | 28 |
gap junction | 28 |
prospective cohort | 28 |
simplex virus | 28 |
receptor agonist | 28 |
old male | 28 |
significant role | 28 |
chest pain | 28 |
lung metastasis | 28 |
bronchial epithelial | 27 |
hematopoietic cells | 27 |
mean apache | 27 |
using anti | 27 |
cellular processes | 27 |
patient safety | 27 |
neonatal rat | 27 |
survival rates | 27 |
markedly increased | 27 |
may indicate | 27 |
parenteral nutrition | 27 |
cerebral endothelial | 27 |
liver damage | 27 |
blood donors | 27 |
increased production | 27 |
inhibitory activity | 27 |
fio ratio | 27 |
cytometric analysis | 27 |
independently associated | 27 |
metabolic pathways | 27 |
body surface | 27 |
confidence interval | 27 |
diagnostic criteria | 27 |
intracranial pressure | 27 |
pct levels | 27 |
lps ifn | 27 |
severity scores | 27 |
porcine reproductive | 27 |
trpc channels | 27 |
recently demonstrated | 27 |
might contribute | 27 |
goat anti | 27 |
receptor antagonists | 27 |
antimicrobial activity | 27 |
showed significantly | 27 |
combination therapy | 27 |
phase ii | 27 |
villous explants | 27 |
results demonstrated | 27 |
study included | 27 |
oxygen tension | 27 |
cirrhotic patients | 27 |
human blood | 27 |
early stages | 27 |
two distinct | 27 |
dependent protein | 27 |
fungal infection | 27 |
shock protein | 27 |
paraffin embedded | 27 |
mean duration | 27 |
burn injury | 27 |
allergic asthma | 27 |
human serum | 27 |
shear stress | 27 |
graphpad prism | 27 |
lpz mpsl | 27 |
recent evidence | 27 |
proteins involved | 27 |
high expression | 27 |
chronic pain | 27 |
tract infections | 27 |
independent risk | 27 |
challenged wt | 27 |
oxygen extraction | 27 |
mitochondrial dysfunction | 27 |
elisa kits | 27 |
high mobility | 27 |
evaluate whether | 27 |
signaling via | 27 |
neurological outcome | 27 |
large amounts | 27 |
chi square | 27 |
present data | 27 |
human endometrium | 27 |
two types | 27 |
data support | 27 |
general icu | 27 |
inflammatory mediator | 26 |
statistical analyses | 26 |
cruz biotechnology | 26 |
pulmonary infection | 26 |
fetal sheep | 26 |
anova followed | 26 |
controlled study | 26 |
intestinal inflammation | 26 |
injury model | 26 |
ms lesions | 26 |
much higher | 26 |
cardiovascular diseases | 26 |
improved survival | 26 |
increasing concentrations | 26 |
mice infected | 26 |
jugular bulb | 26 |
sepsis model | 26 |
non invasive | 26 |
fluorescent protein | 26 |
recently identified | 26 |
respiratory signs | 26 |
showed increased | 26 |
dependent increase | 26 |
nursing staff | 26 |
increasing evidence | 26 |
dna binding | 26 |
expression may | 26 |
group iii | 26 |
using spss | 26 |
patients compared | 26 |
carbon dioxide | 26 |
cellular response | 26 |
surviving sepsis | 26 |
fetal lung | 26 |
negative sepsis | 26 |
single dose | 26 |
anp low | 26 |
comet assay | 26 |
increased compared | 26 |
secondary antibodies | 26 |
cell interactions | 26 |
previous findings | 26 |
experimental autoimmune | 26 |
following parameters | 26 |
statistically different | 26 |
neutrophil activation | 26 |
study investigated | 26 |
quantitative analysis | 26 |
died within | 26 |
broad spectrum | 26 |
recipient mice | 26 |
pathways involved | 26 |
neuronal cells | 26 |
use committee | 26 |
cells compared | 26 |
surfactant lipids | 26 |
kupffer cell | 26 |
protects mice | 26 |
host defence | 26 |
lung compliance | 26 |
rat lung | 26 |
steady state | 26 |
experimental conditions | 26 |
antimicrobial peptides | 26 |
mouse macrophages | 26 |
induced pulmonary | 26 |
including tnf | 26 |
nerve injury | 26 |
study aims | 26 |
naturally occurring | 26 |
ten patients | 26 |
high frequency | 25 |
regression model | 25 |
genomic dna | 25 |
increased il | 25 |
human myometrial | 25 |
airway management | 25 |
human health | 25 |
intestinal ischemia | 25 |
effective treatment | 25 |
rough lps | 25 |
cold pbs | 25 |
decreased expression | 25 |
acid residues | 25 |
enzymatic activity | 25 |
fluorescence intensity | 25 |
bacterial clearance | 25 |
results suggested | 25 |
persistent pulmonary | 25 |
per se | 25 |
membrane oxygenation | 25 |
vivo model | 25 |
mdck cells | 25 |
also expressed | 25 |
remains unknown | 25 |
cellular responses | 25 |
molecular biology | 25 |
autoimmune disease | 25 |
kg i | 25 |
results may | 25 |
well understood | 25 |
marginated neutrophils | 25 |
receptor complex | 25 |
significantly suppressed | 25 |
autoimmune encephalomyelitis | 25 |
clinical features | 25 |
therapeutic approach | 25 |
brain damage | 25 |
days following | 25 |
positive blood | 25 |
play important | 25 |
experiments revealed | 25 |
experimental group | 25 |
bacterial growth | 25 |
bovine lactoferrin | 25 |
antithrombin iii | 25 |
chronic lung | 25 |
via tlr | 25 |
irg cad | 25 |
drug development | 25 |
following trauma | 25 |
two major | 25 |
mice deficient | 25 |
abdominal pain | 25 |
invasive mechanical | 25 |
grey matter | 25 |
oxide production | 25 |
support ventilation | 25 |
induced septic | 25 |
normal pregnancies | 25 |
treated controls | 25 |
also present | 25 |
tyrosine phosphorylation | 25 |
mediated immunity | 25 |
maternal plasma | 25 |
injury score | 25 |
cells following | 25 |
barrier dysfunction | 25 |
brain death | 25 |
therapeutic interventions | 25 |
overall mortality | 25 |
induced tlr | 25 |
see table | 25 |
inhalation injury | 25 |
biologically active | 25 |
dna vaccine | 25 |
biological effects | 25 |
food intake | 25 |
much lower | 25 |
research institute | 25 |
correlation coefficient | 25 |
late gestation | 25 |
experimental animals | 25 |
detected using | 25 |
strongly suggest | 25 |
therapeutic effects | 25 |
dna double | 25 |
airway epithelial | 25 |
potential target | 25 |
barrier integrity | 25 |
maternal age | 25 |
arterial oxygen | 25 |
experimental studies | 25 |
well defined | 25 |
chronic hepatitis | 25 |
lesser extent | 24 |
myeloid differentiation | 24 |
pregnant mice | 24 |
early postoperative | 24 |
may occur | 24 |
circulating levels | 24 |
tissue culture | 24 |
first study | 24 |
cerebrospinal fluid | 24 |
specific antibody | 24 |
control subjects | 24 |
cell recruitment | 24 |
palliative care | 24 |
conjugated anti | 24 |
fluid balance | 24 |
also performed | 24 |
double strand | 24 |
cell sorting | 24 |
without affecting | 24 |
intrauterine growth | 24 |
activator inhibitor | 24 |
human disease | 24 |
mice expressing | 24 |
cross talk | 24 |
applied biosystems | 24 |
cycle progression | 24 |
adenylate cyclase | 24 |
synaptic plasticity | 24 |
test whether | 24 |
target proteins | 24 |
demyelinated axons | 24 |
cells derived | 24 |
neuronal death | 24 |
increased pulmonary | 24 |
human monocyte | 24 |
tlr md | 24 |
lineage cells | 24 |
human pulmonary | 24 |
single nucleotide | 24 |
fi rst | 24 |
spleen cells | 24 |
lactic acid | 24 |
monocyte macrophage | 24 |
significant effect | 24 |
one hundred | 24 |
matrix metalloproteinases | 24 |
seven patients | 24 |
prognostic factors | 24 |
fetal weight | 24 |
primary antibody | 24 |
supine position | 24 |
enteral nutrition | 24 |
interquartile range | 24 |
patients presented | 24 |
concentration range | 24 |
cells expressed | 24 |
immune complex | 24 |
medical history | 24 |
new york | 24 |
clinical characteristics | 24 |
cells ml | 24 |
animals received | 24 |
serum amyloid | 24 |
nosocomial infection | 24 |
cerebral blood | 24 |
blood circulation | 24 |
disease activity | 24 |
also used | 24 |
irg expression | 24 |
obstetrics gynecology | 24 |
one case | 24 |
hepatitis patients | 24 |
schwann cell | 24 |
liver tissue | 24 |
medical intensive | 24 |
phase proteins | 24 |
induced dna | 24 |
study conducted | 24 |
inflammatory lung | 24 |
immunoblot analysis | 24 |
patient care | 24 |
colon cancer | 24 |
specific immune | 24 |
trophoblast cell | 24 |
dependent mechanism | 24 |
tnf levels | 24 |
human cells | 24 |
mm nacl | 24 |
per patient | 24 |
coagulation system | 24 |
four patients | 24 |
calculated using | 24 |
tertiary care | 24 |
genes encoding | 24 |
high incidence | 23 |
elisa kit | 23 |
paraffin sections | 23 |
published data | 23 |
inflammatory genes | 23 |
septic complications | 23 |
liver cells | 23 |
initial dose | 23 |
functional changes | 23 |
among others | 23 |
promising therapeutic | 23 |
gene regulation | 23 |
analysis demonstrated | 23 |
might also | 23 |
candidate genes | 23 |
give rise | 23 |
consecutive days | 23 |
kidney disease | 23 |
injured patients | 23 |
primary cultures | 23 |
oligodendrocyte precursor | 23 |
first week | 23 |
infectious disease | 23 |
long time | 23 |
bowel necrosis | 23 |
adult male | 23 |
median time | 23 |
ultrasound treatment | 23 |
examined whether | 23 |
inhibited lps | 23 |
acute brain | 23 |
mouse brain | 23 |
whole body | 23 |
tir domain | 23 |
lipid rafts | 23 |
postoperative day | 23 |
matrix metalloproteinase | 23 |
observation period | 23 |
humoral immune | 23 |
derived cells | 23 |
lung damage | 23 |
protein interactions | 23 |
growth hormone | 23 |
glucose tolerance | 23 |
mediated inhibition | 23 |
stably transfected | 23 |
edema formation | 23 |
experimental groups | 23 |
specific inhibitors | 23 |
cd antibody | 23 |
also measured | 23 |
cells also | 23 |
useful tool | 23 |
multiple comparisons | 23 |
virus infections | 23 |
general anesthesia | 23 |
respiratory mechanics | 23 |
gnrh ii | 23 |
different groups | 23 |
protective immunity | 23 |
fold change | 23 |
femoral artery | 23 |
induced production | 23 |
miu ml | 23 |
induced colitis | 23 |
granulocyte colony | 23 |
antibody production | 23 |
ace activity | 23 |
ng kg | 23 |
aea levels | 23 |
via activation | 23 |
newborn offspring | 23 |
allergic inflammation | 23 |
receptor family | 23 |
mice challenged | 23 |
mice displayed | 23 |
cells well | 23 |
sofa scores | 23 |
still unknown | 23 |
intestinal injury | 23 |
using standard | 23 |
might play | 23 |
major abdominal | 23 |
phosphate buffer | 23 |
urine samples | 23 |
ca influx | 23 |
receptor signalling | 23 |
lung vascular | 23 |
baseline characteristics | 23 |
dose response | 23 |
wet dry | 23 |
different mechanisms | 23 |
mouse monoclonal | 23 |
mechanism underlying | 23 |
increased vascular | 23 |
immunohistochemical staining | 23 |
experiments using | 23 |
intravenous administration | 23 |
extracellular space | 23 |
adaptor protein | 23 |
common complication | 23 |
ventilatory support | 23 |
delivery system | 23 |
steroid hormones | 23 |
may improve | 22 |
er stress | 22 |
mhc i | 22 |
null mice | 22 |
analyses revealed | 22 |
phase protein | 22 |
emergency room | 22 |
primary tumor | 22 |
pge production | 22 |
cns inflammation | 22 |
lymphocyte proliferation | 22 |
intracranial hypertension | 22 |
phase i | 22 |
trizol reagent | 22 |
inflammatory pathways | 22 |
lung fibroblasts | 22 |
fl fl | 22 |
acute exacerbations | 22 |
itaconic acid | 22 |
allergic airway | 22 |
sepsis campaign | 22 |
cell activity | 22 |
vivo experiments | 22 |
mucosal barrier | 22 |
membrane proteins | 22 |
tipe overexpression | 22 |
syndrome virus | 22 |
hemodynamic changes | 22 |
collagen deposition | 22 |
primary mouse | 22 |
surface receptors | 22 |
gene therapy | 22 |
cell specific | 22 |
lung collectins | 22 |
full length | 22 |
soluble tnf | 22 |
hypoxic pulmonary | 22 |
infectious complications | 22 |
patient outcome | 22 |
assay using | 22 |
function tests | 22 |
mediated gene | 22 |
channel activity | 22 |
i min | 22 |
animal testing | 22 |
among women | 22 |
local inflammatory | 22 |
lp group | 22 |
serum tnf | 22 |
positive staining | 22 |
mean sem | 22 |
baseline values | 22 |
cultured astrocytes | 22 |
density gradient | 22 |
nerve fibers | 22 |
transduction pathway | 22 |
mature oligodendrocytes | 22 |
cell damage | 22 |
erk activation | 22 |
cd monocytes | 22 |
pasteurella multocida | 22 |
liquid nitrogen | 22 |
least three | 22 |
myeloid cell | 22 |
showed similar | 22 |
tnf alpha | 22 |
whole genome | 22 |
alveolar macrophage | 22 |
factors may | 22 |
pam csk | 22 |
tlr stimulation | 22 |
higher risk | 22 |
table shows | 22 |
bordetella bronchiseptica | 22 |
four groups | 22 |
cytokine gene | 22 |
cell transformation | 22 |
serum concentrations | 22 |
well characterized | 22 |
tail vein | 22 |
will provide | 22 |
atopic dermatitis | 22 |
cholera toxin | 22 |
metabolic alkalosis | 22 |
adoptive transfer | 22 |
ventricular function | 22 |
competing interests | 22 |
intestinal epithelium | 22 |
may reflect | 22 |
acid use | 22 |
mice fed | 22 |
way analysis | 22 |
scavenger receptor | 22 |
vibrating mesh | 22 |
extracorporeal membrane | 22 |
marrow derived | 22 |
rats subjected | 22 |
two cases | 22 |
molecule expression | 22 |
cells exposed | 22 |
clinical conditions | 22 |
receptor mrna | 22 |
vena cava | 21 |
kinase activity | 21 |
infectious agents | 21 |
studies revealed | 21 |
breathing pattern | 21 |
helicobacter pylori | 21 |
septic mice | 21 |
physiological role | 21 |
also suggest | 21 |
common cause | 21 |
induced phosphorylation | 21 |
cord injury | 21 |
septic animals | 21 |
cognitive impairment | 21 |
signalling molecules | 21 |
medical centre | 21 |
respiratory alkalosis | 21 |
case report | 21 |
prospectively collected | 21 |
macrophage inflammatory | 21 |
drug administration | 21 |
calcium channel | 21 |
brain slices | 21 |
molecular basis | 21 |
treatment significantly | 21 |
placental tissue | 21 |
camp levels | 21 |
adaptor proteins | 21 |
response element | 21 |
surgery patients | 21 |
cardiac dysfunction | 21 |
human uterine | 21 |
severe liver | 21 |
higher level | 21 |
uterine emg | 21 |
human placental | 21 |
factors including | 21 |
sybr green | 21 |
horseradish peroxidase | 21 |
also able | 21 |
protein content | 21 |
rank test | 21 |
induced changes | 21 |
blood transfusions | 21 |
rats treated | 21 |
repeated measures | 21 |
receptor binding | 21 |
icu staff | 21 |
hepatic failure | 21 |
active form | 21 |
allowed us | 21 |
oxygen therapy | 21 |
healthy control | 21 |
also induced | 21 |
dominant negative | 21 |
inflammatory changes | 21 |
polyclonal antibodies | 21 |
surgical intensive | 21 |
vascular dilatation | 21 |
ic bps | 21 |
sensory neurons | 21 |
experimental data | 21 |
intravascular volume | 21 |
results support | 21 |
right ventricle | 21 |
normal controls | 21 |
lung cells | 21 |
may act | 21 |
completely abolished | 21 |
mice injected | 21 |
defense mechanisms | 21 |
mm tris | 21 |
various inflammatory | 21 |
lung wet | 21 |
artery occlusion | 21 |
hepg cells | 21 |
ischemic injury | 21 |
density lipoprotein | 21 |
final concentration | 21 |
vs control | 21 |
muscle cell | 21 |
transcriptional activity | 21 |
nosocomial infections | 21 |
invading pathogens | 21 |
tumor development | 21 |
also tested | 21 |
basal level | 21 |
associated lymphoid | 21 |
ligand binding | 21 |
electrical activity | 21 |
enhanced expression | 21 |
clotting factors | 21 |
vascular leakage | 21 |
mm edta | 21 |
inhaled nitric | 21 |
despite enhanced | 21 |
ii scores | 21 |
cultured cells | 21 |
murine models | 21 |
patients hospitalized | 21 |
following injury | 21 |
low pmn | 21 |
lps binding | 21 |
blood sampling | 21 |
effects may | 21 |
fold lower | 21 |
hospital length | 21 |
improve survival | 21 |
one hand | 21 |
i receptor | 21 |
i levels | 21 |
human fetal | 21 |
respiratory epithelium | 21 |
regulatory mechanisms | 21 |
ge healthcare | 21 |
assess whether | 21 |
postoperative complications | 21 |
pelvic organ | 21 |
relatively low | 21 |
polyacrylamide gel | 21 |
second lps | 21 |
may increase | 21 |
cells isolated | 21 |
risk patients | 21 |
lung infl | 21 |
patients presenting | 21 |
venous catheter | 20 |
sialic acid | 20 |
placebo group | 20 |
induced neutrophil | 20 |
injured mice | 20 |
induced nf | 20 |
main cause | 20 |
nuclear protein | 20 |
written informed | 20 |
physiological functions | 20 |
rat liver | 20 |
mtt assay | 20 |
patient population | 20 |
active site | 20 |
wedge pressure | 20 |
oxygen transport | 20 |
operating characteristic | 20 |
care bundle | 20 |
guanylate cyclase | 20 |
patients included | 20 |
day survival | 20 |
key factor | 20 |
sodium dodecyl | 20 |
oxygen free | 20 |
general population | 20 |
vital signs | 20 |
icu admissions | 20 |
control values | 20 |
caesarean section | 20 |
fully understood | 20 |
hospital admission | 20 |
using high | 20 |
lps elastase | 20 |
bacterial products | 20 |
lung endothelial | 20 |
reduced levels | 20 |
within one | 20 |
left ventricle | 20 |
vitro methods | 20 |
various types | 20 |
human heart | 20 |
tested using | 20 |
complex i | 20 |
alexa fluor | 20 |
neutralizing antibodies | 20 |
interstitial edema | 20 |
cell injury | 20 |
antimicrobial therapy | 20 |
lc ms | 20 |
meconium passage | 20 |
onset preeclampsia | 20 |
oxygen radicals | 20 |
chronic pelvic | 20 |
virus replication | 20 |
primary microglia | 20 |
inspiratory pressure | 20 |
iu ml | 20 |
plasmid dna | 20 |
analysis indicated | 20 |
three weeks | 20 |
neonatal mice | 20 |
multiorgan failure | 20 |
hcv infection | 20 |
deficient pmcs | 20 |
sepsis induced | 20 |
superoxide production | 20 |
ra patients | 20 |
blood products | 20 |
extracellular signal | 20 |
protein sp | 20 |
lps treated | 20 |
pregnancy outcome | 20 |
post infection | 20 |
cardiac myocytes | 20 |
sepsis group | 20 |
gene encoding | 20 |
joint inflammation | 20 |
selective inhibition | 20 |
levels may | 20 |
hyaluronic acid | 20 |
rabbit igg | 20 |
carcinoma cells | 20 |
developmental stages | 20 |
will also | 20 |
mice using | 20 |
four hours | 20 |
ii cells | 20 |
cellular stress | 20 |
vitro models | 20 |
specific binding | 20 |
cognitive decline | 20 |
currently available | 20 |
pulmonary vasoconstriction | 20 |
likely due | 20 |
using trizol | 20 |
conjugated secondary | 20 |
positive effect | 20 |
lymphoid organs | 20 |
treated groups | 20 |
induced vascular | 20 |
luteal cells | 20 |
complement factor | 20 |
maternal blood | 20 |
chronic disease | 20 |
mainly due | 20 |
study population | 20 |
organ system | 20 |
severe disease | 20 |
within min | 20 |
breast milk | 20 |
higher expression | 20 |
untreated cells | 20 |
least two | 20 |
regulatory role | 20 |
mediated inflammation | 20 |
neuronal cell | 20 |
clostridium difficile | 20 |
increased activity | 20 |
also assessed | 20 |
rac nitration | 20 |
remained stable | 20 |
two cell | 20 |
isolated using | 20 |
green fluorescent | 20 |
histological examination | 20 |
lactation period | 20 |
related protein | 20 |
vivo data | 20 |
less pronounced | 20 |
infected individuals | 19 |
right lung | 19 |
transcriptional regulators | 19 |
increased permeability | 19 |
protease inhibitors | 19 |
plasma aea | 19 |
negative feedback | 19 |
hoc test | 19 |
primary rat | 19 |
monocyte chemoattractant | 19 |
life support | 19 |
novel mechanism | 19 |
elective cesarean | 19 |
animals showed | 19 |
immune tolerance | 19 |
inflammatory drugs | 19 |
cell transplantation | 19 |
protein complex | 19 |
expression changes | 19 |
antibodies directed | 19 |
still remains | 19 |
will focus | 19 |
past years | 19 |
pulmonary pathology | 19 |
term outcome | 19 |
hematopoietic stem | 19 |
tlr gene | 19 |
silver nanoparticles | 19 |
potent inhibitor | 19 |
increased blood | 19 |
unclear whether | 19 |
core temperature | 19 |
bacterial sepsis | 19 |
every day | 19 |
took place | 19 |
luciferase activity | 19 |
relatively high | 19 |
respiratory insufficiency | 19 |
cerebral ischemia | 19 |
plasma tnf | 19 |
alternative pathway | 19 |
tnf receptors | 19 |
mice exposed | 19 |
lethal dose | 19 |
palm expression | 19 |
transmission electron | 19 |
bacterial cell | 19 |
per ml | 19 |
also investigated | 19 |
oligodendrocyte progenitor | 19 |
year mortality | 19 |
thrombin generation | 19 |
male offspring | 19 |
collected data | 19 |
activation markers | 19 |
burned patients | 19 |
i ifn | 19 |
inotropic support | 19 |
irf activity | 19 |
reverse transcriptase | 19 |
vivo models | 19 |
endotoxin induced | 19 |
angiotensin converting | 19 |
colorectal cancer | 19 |
change significantly | 19 |
action potential | 19 |
imperial college | 19 |
normal values | 19 |
important mediator | 19 |
colon carcinoma | 19 |
cell maturation | 19 |
undergoing cardiac | 19 |
perfusion pressure | 19 |
small molecules | 19 |
particle size | 19 |
platelet activating | 19 |
every hours | 19 |
human brain | 19 |
randomly divided | 19 |
propidium iodide | 19 |
induced airway | 19 |
energy expenditure | 19 |
glutamate uptake | 19 |
still unclear | 19 |
endotracheal intubation | 19 |
days prior | 19 |
transcriptional level | 19 |
neurite outgrowth | 19 |
recently described | 19 |
tlr signalling | 19 |
care med | 19 |
protein assay | 19 |
endotoxemic mice | 19 |
endothelial function | 19 |
septic response | 19 |
mitogen activated | 19 |
clinical parameters | 19 |
western blots | 19 |
mg day | 19 |
costimulatory molecules | 19 |
using different | 19 |
lung water | 19 |
disease patients | 19 |
euglena tuba | 19 |
intravenous infusion | 19 |
cell tolerance | 19 |
flow cytometer | 19 |
receptor protein | 19 |
plasma endotoxin | 19 |
coagulation cascade | 19 |
patients following | 19 |
reproductive sciences | 19 |
primary cultured | 19 |
also inhibited | 19 |
hours following | 19 |
regulatory proteins | 19 |
nine patients | 19 |
hypovolemic shock | 19 |
monocytic cells | 19 |
also revealed | 19 |
showed higher | 19 |
equal amounts | 19 |
intracellular camp | 19 |
test system | 19 |
cd cell | 19 |
showed high | 19 |
white cell | 19 |
corpus callosum | 19 |
recently reported | 19 |
tlr mrna | 19 |
light microscope | 19 |
may suggest | 19 |
phase response | 19 |
higher rate | 19 |
epidemiological studies | 19 |
adverse outcomes | 19 |
lung transplantation | 19 |
chart review | 19 |
weeks post | 19 |
placental abruption | 19 |
pertussis toxin | 19 |
bacterial lps | 19 |
serum concentration | 19 |
preterm labour | 19 |
base excess | 19 |
may induce | 19 |
pulmonary rehabilitation | 19 |
diseases including | 19 |
mechanisms responsible | 19 |
chemoattractant protein | 19 |
genetic background | 19 |
microvascular permeability | 19 |
one patients | 19 |
shed blood | 19 |
tissue inflammation | 19 |
phosphorylation sites | 19 |
may therefore | 19 |
therapeutic agent | 19 |
vitro stimulation | 19 |
inflammasome pathway | 19 |
potassium channels | 19 |
selectin expression | 19 |
proliferative response | 19 |
alternative splicing | 19 |
vast majority | 19 |
biological processes | 19 |
will help | 19 |
situ hybridization | 19 |
biological activities | 19 |
also evaluated | 19 |
intracellular signaling | 19 |
vagus nerve | 19 |
equal volume | 19 |
culture conditions | 19 |
major component | 18 |
aki stage | 18 |
derived dendritic | 18 |
ml saline | 18 |
graphpad software | 18 |
mesenteric arteries | 18 |
newly developed | 18 |
eight patients | 18 |
concentration dependent | 18 |
pol ii | 18 |
risk stratification | 18 |
plasma il | 18 |
right heart | 18 |
slight increase | 18 |
experimental sepsis | 18 |
science foundation | 18 |
pg kg | 18 |
significant association | 18 |
intubated patients | 18 |
one group | 18 |
refractory ascites | 18 |
neutrophilic inflammation | 18 |
cd foxp | 18 |
tandem mass | 18 |
lactate dehydrogenase | 18 |
evidence indicates | 18 |
adult rats | 18 |
ards mice | 18 |
stimulated macrophages | 18 |
previous results | 18 |
bacterial peritonitis | 18 |
provide new | 18 |
fetal dna | 18 |
cytotoxic effect | 18 |
expressing cd | 18 |
mesenteric lymph | 18 |
remain unclear | 18 |
expiratory flow | 18 |
whole cell | 18 |
traumatic injury | 18 |
tlr ko | 18 |
optical density | 18 |
macrophage polarization | 18 |
cfhr deletion | 18 |
prrsv infection | 18 |
isotype control | 18 |
pharmacological inhibition | 18 |
smooth lps | 18 |
relative expression | 18 |
neonatal outcomes | 18 |
effector functions | 18 |
green tea | 18 |
identifi ed | 18 |
degradation products | 18 |
isolated human | 18 |
inhibits lps | 18 |
cell morphology | 18 |
ringo spy | 18 |
crystal structure | 18 |
ammatory response | 18 |